These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Evaluation of a filtration lymphocytapheresis (LCP) device for use in the treatment of patients with rheumatoid arthritis. Kondoh T; Hidaka Y; Katoh H; Inoue N; Saito S Artif Organs; 1991 Jun; 15(3):180-8. PubMed ID: 1867528 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of ulcerative colitis with leukocytapheresis using non-woven polyester filter. Sakata H; Kawamura N; Horie T; Ohizumi H; Tamaki T; Kukita K; Meguro J; Yonekawa M; Saitoh M; Kawamura A Ther Apher Dial; 2003 Dec; 7(6):536-9. PubMed ID: 15018240 [TBL] [Abstract][Full Text] [Related]
8. Developments in the apheresis procedure for the treatment of inflammatory bowel disease. Pineda AA Inflamm Bowel Dis; 2006 Jan; 12 Suppl 1():S10-4. PubMed ID: 16378005 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of multiple sclerosis with lymphocytapheresis using a leukocyte adsorption column]. Sato T; Imamura N; Nozaki K; Ishigaki Y Nihon Rinsho; 1994 Nov; 52(11):3032-7. PubMed ID: 7996706 [TBL] [Abstract][Full Text] [Related]
11. Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease. Mitsuyama K; Yamasaki H; Kuwaki K; Takedatsu H; Sata M Curr Pharm Des; 2009; 15(18):2110-9. PubMed ID: 19519448 [TBL] [Abstract][Full Text] [Related]
12. Treatment of inflammatory immunologic disease 1. Leukocytapheresis for inflammatory immunologic disease (tentative). Watanabe M; Kubota D; Nagahori M; Kanai T Intern Med; 2007; 46(16):1305-6. PubMed ID: 17704611 [No Abstract] [Full Text] [Related]
13. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease. Kawamura A; Saitoh M; Yonekawa M; Horie T; Ohizumi H; Tamaki T; Kukita K; Meguro J Ther Apher; 1999 Nov; 3(4):334-7. PubMed ID: 10608731 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of plasmapheresis or leukocytapheresis for articular and extraarticular manifestations of rheumatoid arthritis. Ogawa H; Matsumoto Y Ther Apher; 1997 Nov; 1(4):330-5. PubMed ID: 10225725 [TBL] [Abstract][Full Text] [Related]
16. Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Sawada K Dis Colon Rectum; 2003 Oct; 46(10 Suppl):S66-77. PubMed ID: 14530661 [TBL] [Abstract][Full Text] [Related]
17. Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis. Onuma S; Yamaji K; Kempe K; Ogasawara M; Ogawa T; Yang K; Kanai M; Tsuda H; Takasaki Y Ther Apher Dial; 2006 Oct; 10(5):404-11. PubMed ID: 17096694 [TBL] [Abstract][Full Text] [Related]
18. Millennium Memorabilia Issue on Apheresis: part 2. Centrifugal devices, adsorbents, leukocyte filters, and extracorporeal immunomodulations. Murabayashi S Ther Apher; 2000 Apr; 4(2):71-2. PubMed ID: 10805422 [No Abstract] [Full Text] [Related]
19. Improved on-line thoracic duct drainage for lymphocytapheresis. Sato T; Koga N; Nagano T; Ohteki H; Masuda T; Agishi T Int J Artif Organs; 1991 Dec; 14(12):800-4. PubMed ID: 1783455 [TBL] [Abstract][Full Text] [Related]
20. Effect of various anticoagulant agents on large-volume leukocytapheresis using new Cellsorba CS-180S Filter. Hohtatsu K; Yamaji K; Yamada R; Oda K; Kageyama M; Kusaoi M; Onuma S; Kawamoto T; Sugimoto K; Sekiya F; Kon T; Ogasawara M; Kempe K; Tsuda H; Takasaki Y Ther Apher Dial; 2011 Aug; 15(4):355-9. PubMed ID: 21884469 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]